However, it is more likely that anti-EGFR mAbs may impede the identification of endothelial damage resulting from co-administered agents, thus facilitating platelet activation, leukocyte adhesion, oxidative stress, coagulation, and inflammation—all of which are integral to thromboembolism development. This evidence concerns the gene EGFR and Thromboembolism.